KHOTT BIOTECH Advances Smart Wound Care with Strategic Grant Funding and Global Recognition
KHOTT BIOTECH Ltd, the UK‑registered biotech start‑up working on smart photodynamic therapy for chronic wound care, has been advancing its funding and support journey through competitive grants and innovation programmes that inject crucial non‑dilutive capital into its early stage development. Founded in March 2025 and headquartered at the Faculty of Life Sciences, University of Bradford, the company is focused on its flagship therapeutic wearable device, the PDPatchᵀᴹ, which combines infection control and tissue regeneration with real‑time monitoring to address the global challenge of chronic wounds and antimicrobial resistance.
While KHOTT BIOTECH has not publicly disclosed traditional venture capital rounds or named institutional investors, the company has secured meaningful funding from competitive research and innovation grant sources that are helping bridge the gap between academic proof‑of‑concept and potential commercial deployment. A major milestone in this journey was the receipt of £200,000 in non‑dilutive funding through programmes such as the NIHR i4i THRIVE funding stream supported by the National Institute for Health and Care Research (NIHR) and the EPSRC Impact Accelerator, programmes designed to accelerate healthcare innovations through structured grants and entrepreneurial support. This funding award provides capital specifically targeted at early‑stage development, prototyping and market validation activities that can transform the PDPatch technology from laboratory innovation toward real‑world use.
The NIHR i4i THRIVE programme, which supports clinical and research‑led projects that demonstrate early proof‑of‑concept, offers financial backing alongside intensive entrepreneurial training and mentorship designed to help biomedical innovations progress toward commercial readiness. As a funding stream that prioritises translational impact — particularly for technologies that address health inequalities and unmet clinical needs — this grant has been a key part of enabling KHOTT BIOTECH to validate its wearable photodynamic therapeutic device in contexts that could lead to NHS and global healthcare adoption.
The company’s approach to funding underscores a broader trend among deep‑tech healthcare start‑ups where strategic, early grant funding lays the groundwork for later institutional investment. KHOTT BIOTECH’s ability to compete successfully for these awards — particularly against established research‑led competitors — demonstrates confidence from public research funders in its novel therapeutic platform and the potential of its PDPatch device to transform chronic wound care. This early success in grant funding not only injects capital but also connects the start‑up with high‑value networks, clinical partners, and regulatory training that are essential for future growth.
In addition to direct funding, KHOTT BIOTECH’s presence on international innovation stages further enhances its visibility to potential investors and strategic partners. In September 2025, the company was awarded Third Prize in the 2025 Entrepreneurs Next Star & Million Prize Global Challenge (Europe Track) — an international competition that attracts ambitious start‑ups from around the world and offers winners access to incubation support, workspace opportunities and market entry assistance, particularly in China’s innovation ecosystem. This recognition not only highlights the commercial potential of the PDPatch technology but also opens doors to broader funding networks and possible future partnerships with corporate or institutional investors.
KHOTT BIOTECH’s leadership team, led by founder and CEO Dr Ibrahim Khot, collaborates with a strong advisory board that includes experienced entrepreneurs and biomedical experts, positioning the company to make strategic decisions about future funding rounds as it progresses through clinical evaluation and regulatory planning. The company’s innovation — a smart wearable device that integrates photodynamic therapy with AI‑enabled remote monitoring — addresses critical gaps in chronic wound management, where millions of patients worldwide suffer from persistent infections and costly, debilitating outcomes.
Looking ahead, KHOTT BIOTECH’s funding trajectory appears centred on leveraging research and clinical grants to validate and de‑risk its technology, making it attractive to potential venture capital or strategic medical device investors in later stages. As the PDPatch moves closer to clinical demonstration and regulatory pathways, the company is well positioned to seek institutional backing that can accelerate commercialisation and global rollout.
Although traditional equity funding has not yet been publicly recorded for KHOTT BIOTECH, its success in securing competitive grant funding and international innovation accolades reflects a strong early‑stage validation of its business model and technology. These achievements lay the foundation for future capital raises that could support manufacturing scale‑up, regulatory approvals and broader market entry into a multi‑billion‑dollar wound care and infection management sector.
